Alkermes Files Vivitrex NDA; Alcoholism Drug May Have Compliance Benefit
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alkermes' Vivitrex is on to track to become the first once-monthly injection for alcohol dependence, providing a potential advantage for patient-compliance monitoring over competitors, the firm says